BridgeBio Oncology Therapeutics, Inc. Common Stock BBOT
$6.75
-23.76%
at last close
Market Cap$710.34 million
P/E Ratio—
Div Yield—
Volume1.50M
52-Week Range
$6.29$14.87
Analyst Ratings
- Consensus
- Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $22.56 (+233.9% upside)
Key Stats
- Today's Range
- $6.29 – $8.86
- 50-Day Range
- $6.29 – $9.78
- 52-Week Range
- $6.29 – $14.87
- Volume
- 1.50 million shs
- Average Volume
- 301K shs
- Market Cap
- $710.34 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.05%
- Days to Cover
- 1.00
About BridgeBio Oncology Therapeutics, Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Related Stocks
Compare head-to-head: BBOT vs LLY·BBOT vs JNJ·BBOT vs ABBV·BBOT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.